Enspryng 120 mg (Satralizumab SOLUTION) 120 MG

ENSPRYNG 120 MG is a subcutaneous solution containing satralizumab, used for managing certain autoimmune conditions. This medication is designed to help control symptoms and improve quality of life for eligible patients.

Strength

120 MG

Manufacturer / TM Owner

HOFFMANN-LA ROCHE LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ENSPRYNG 120 MG is primarily used for the treatment of specific autoimmune disorders. It works by targeting certain immune system pathways to reduce inflammation and other symptoms associated with these conditions. Patients often wonder, 'What is ENSPRYNG used for?' and the answer lies in its ability to manage symptoms of autoimmune diseases effectively.

Side Effects

Common effects of ENSPRYNG 120 MG may include injection site reactions, such as redness or swelling. Some users might experience fatigue or mild gastrointestinal discomfort. These effects are generally mild and temporary, but it's important to monitor any persistent or severe reactions.

Precautions & Warnings

ENSPRYNG 120 MG should be handled with care, ensuring proper storage and administration techniques. Patients should follow their healthcare provider's instructions for subcutaneous use. It's crucial to inform your healthcare provider about any allergies or existing medical conditions before starting this medication.

Avoid Interactions

ENSPRYNG 120 MG may interact with other medications, particularly those that affect the immune system. It's important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness of this medication.

Frequently Asked Questions

ENSPRYNG 120 MG is used for managing certain autoimmune conditions by targeting specific immune system pathways.

ENSPRYNG 120 MG is administered subcutaneously, typically by injection.

Common side effects may include injection site reactions, fatigue, and mild gastrointestinal discomfort.

Potential interactions with other medications should be discussed with a healthcare provider to ensure safety and effectiveness.

Precautions include proper storage, following administration instructions, and informing your healthcare provider about any allergies or medical conditions.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.